Jw Cayman Therapeutics CO JWCTF

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (“relma-cel”) as a potential treatment for systemic lupus erythematosus (“SLE”), and progressed development of products for the treatment of solid tumors, as well as systemic lupus erythematosus (SLE), a chronic autoimmune disease. The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma; and JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases. It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC); JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients; JWATM213 for treating HCC; JWTCR001 for the treatment of various solid tumors; and JWCAR031 for the treatment of small cell lung cancer. In addition, the company engages in drug research and development; medical research and experimental development; import and export handling; and clinical trial and CRO, as well as investment holding activities. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.